Manninen Petri Mikael Form 4 November 02, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Manninen Petri Mikael		Syn	 2. Issuer Name and Ticker or Trading Symbol ENCORIUM GROUP INC [ENCO] 3. Date of Earliest Transaction 				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle)											Middle) 3. D
UNIONINKATU 22			(Mo	onth/Day/Year)				_X_ Director 10% Owner Officer (give title Other (specify below)			
			11/	01/2007							
(Street)			4. If	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
				Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person			
	HELSINKI,	H9 00130						Form filed by More than One Reporting Person			
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
	1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Dat any (Month/Day/Y	Code	4. Securition(A) or Di (Instr. 3,	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Common Stock, \$.001 per share	11/01/2007		J <u>(1)</u>	40,589	A	\$ 2.83 (2)	313,992	I	managing director of NTGLT Pharma BVBA	
	Common Stock, \$.001 per share	11/01/2007		P	2,742	A	\$ 2.67	69,115	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02)

Edgar Filing: Manninen Petri Mikael - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Tit	le and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orNumber	Expiration D	ate	Amou	unt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Unde	rlying	Security	Secur
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	rities	(Instr. 5)	Bene
	Derivative				Securities			(Instr	. 3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
									Amount		
						Date	Expiration	Title	or Number		
						Exercisable	Date	Title	of		
				Code V	(A) (D)				Shares		
				Code v	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Manninen Petri Mikael UNIONINKATU 22	X							
HELSINKI, H9 00130	Λ							

Signatures

Person

/s/ Petri Mikael
Manninen

**Signature of Reporting
Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Mr. Manninen is managing director of NTGLT Pharma BVBA ("NTGLT"). On November 1, 2007, NTGLT became entitled to receive an additional 40,589 shares of Encorium Group, Inc.'s ("Encorium") common stock pursuant to a "hold-back" provision contained in the

- (1) Amended and Restated Combination Agreement dated July 6, 2006 (the "Agreement"), pursuant to which Encorium acquired all of the issued and outstanding stock of Remedium Oy ("Remedium") on November 1, 2006. The Agreement provides that the former stockholders of Remedium are entitled to receive additional shares of Encorium common stock, for no additional consideration, on the first anniversary of the closing of the business combination.
- The terms of the Agreement provide that for the purpose of determining the number of shares issuable pursuant to the hold-back

 (2) provision, Encorium's common stock would be valued at \$2.83 per share, representing the price per share at which the former Remedium stockholders received Encorium shares upon the closing of the Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2